Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?Zacks Investment Research • 02/05/25
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial ResultsGlobeNewsWire • 01/12/25
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTDGlobeNewsWire • 12/12/24
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformGlobeNewsWire • 11/14/24
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology ConvergenceGlobeNewsWire • 10/21/24
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' NowZacks Investment Research • 08/29/24
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 08/26/24
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a BargainZacks Investment Research • 08/08/24
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewsWire • 08/02/24
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value InvestorsZacks Investment Research • 06/13/24
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full YearGlobeNewsWire • 05/13/24